Prosecution Insights
Last updated: October 21, 2026
Application No. 18/583,042

METHYLOBACTERIUM COMPOSITIONS FOR FUNGAL DISEASE CONTROL

Non-Final OA §103
Filed
Feb 21, 2024
Priority
Dec 09, 2016 — provisional 62/431,927 +3 more
Examiner
TICHY, JENNIFER M.H.
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Newleaf Symbiotics Inc.
OA Round
3 (Non-Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
399 granted / 618 resolved
+4.6% vs TC avg
Strong +34% interview lift
Without
With
+34.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
63 currently pending
Career history
706
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
39.4%
-0.6% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
30.6%
-9.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 618 resolved cases

Office Action

§103
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 20 July 2026 has been entered. Claims 57-61, 64, and 73 have been amended. Claims 62 and 63 have been cancelled. As the elected strain in claim 61 has been removed and placed in claim 57, claim 61 is now considered withdraw, as only non-elected species remain. Claim 74 is newly added, but is withdraw as being drawn to a non-elected invention. Thus, claims 61 and 74 are withdrawn. Claims 57-60 and 64-73 are currently pending and under examination. This Application is a continuation of U.S. Patent Application No. 17/686783, now issued Patent No. 11,930,822, filed March 4, 2022, which is a continuation of U.S. Patent Application No. 16/467384, now issued Patent No. 11,284,622, filed June 6, 2019, which is the 371 National Phase of International Patent Application PCT/US2017/065081, filed December 7, 2017, which claims benefit of priority to U.S. Provisional Patent Application No. 62/431927, filed December 9, 2016. Terminal Disclaimer The terminal disclaimer filed on 20 July 2026 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of U.S. Patent Nos. 11,284,622 and 11,930,822, has been reviewed and is accepted. The terminal disclaimer has been recorded. Withdrawal of Rejections: The rejection of claim 73 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite, is withdrawn. The rejection of claims 57, 58, 61, 62, and 64-73 on the ground of nonstatutory double patenting as being unpatentable over claims of U.S. Patent No. 11,284,622 and U.S. Patent No. 11,930,822, is withdrawn. The rejection of claims 57-62 and 64-73 under 35 U.S.C. 102(a)(1) as anticipated by Didonato-Tinsley et al., is withdrawn. New Rejections: Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 57-60 and 64-73 are rejected under 35 U.S.C. 103 as being unpatentable over Didonato-Tinsley et al. (IDS; WO 2015/085063; Published June 11, 2015). With regard to claims 57 and 68, Didonato-Tinsley et al. teach a composition for application to a plant or plant part, including to a seed, the composition comprising a co-culture of at least two strains of Methylobacterium (Abs.; Para. 15, 18, 56, 70). The taught Methylobacterium strains include Methylobacterium NLS0109 and Methylobacterium NLS0017 (Ex. 7, Table 6; Para. 74). As Didonato-Tinsley et al. teach a co-culture of at least two strains of Methylobacterium and also expressly teach strains NLS0109 and NLS0017, it would have been obvious to one of ordinary skill in the art to select the two or more Methylobacterium strains from those expressly taught. The Methylobacterium strains are present at a concentration of at least about 5x108, 1x109, 3x1010, or 6x1010 CFU per milliliter (Para. 74), which are fully encompassed within at least 5x107 CFU per milliliter. The composition further comprises a liquid, emulsion, or solid matrix, which is a carrier, and an agriculturally acceptable adjuvant, and/or excipient (Para. 46). Didonato-Tinsley et al. render obvious the composition as claimed, including all components as claimed. As the composition cannot be separated from its functions, application of the composition of Didonato-Tinsley et al. to a plant or plant part would necessarily provide the result of increasing plant yield. With regard to claim 73, Didonato-Tinsley et al. teach that the composition can further comprise an additional biocontrol agent including a beneficial or biopesticidal microorganism other than the Methylobacterium strain (Para. 49). With regard to claim 58, Didonato-Tinsley et al. teach that the composition can further comprise an additional biocontrol agent including a bacterium, fungus, virus, or protozoan (Para. 49). With regard to claim 59, Didonato-Tinsley et al. teach that the composition can further comprise an additional biocontrol agent including Bacillus sp., Pseudomonas sp., Coniothyrium sp., Pantoea sp., Streptomyces sp., and Trichoderma sp. (Para. 49). With regard to claim 60, Didonato-Tinsley et al. teach that the composition can further comprise an additional biocontrol agent including Bacillus subtilis, Bacillus thuringiensis, Bacillus pumilis, Pseudomonas syringae, Trichoderma harzianum, Trichoderma virens, and Streptomyces lydicus strains (Para. 49). With regard to claim 64, Didonato-Tinsley et al. teach that the composition can further comprise a microbial biopesticide, which includes a fungicide (Para. 49, 65). With regard to claims 65-67, Didonato-Tinsley et al. teach that the composition further comprises one or more agriculturally acceptable carriers, adjuvants, and/or excipients, including: woodflours, clays, activated carbon, diatomaceous earth, fine-grain inorganic solids, calcium carbonate, calcium bentonite, kaolin, china clay, talc, perlite, mica, vermiculite, silicas, quartz powder, montmorillonite and mixtures thereof; and polyvinyl acetates, polyvinyl acetate copolymers, hydrolyzed polyvinyl acetates, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers, polyvinyl methyl ether, polyvinyl methyl ether-maleic anhydride copolymer, waxes, latex polymers, celluloses including ethylcelluloses and methylcelluloses, hydroxy methylcelluloses, hydroxypropylcellulose, hydroxymethylpropylcelluloses, polyvinyl pyrrolidones, alginates, dextrins, malto-dextrins, polysaccharides, fats, oils, proteins, karaya gum, jaguar gum, tragacanth gum, polysaccharide gums, mucilage, gum arabics, shellacs, vinylidene chloride polymers and copolymers, soybean-based protein polymers and copolymers, lignosulfonates, acrylic copolymers, starches, polyvinylacrylates, zeins, gelatin, carboxymethylcellulose, chitosan, polyethylene oxide, acrylamide polymers and copolymers, polyhydroxyethyl acrylate, methylacrylamide monomers, alginate, ethylcellulose, polychloroprene and syrups or mixtures thereof (Para. 16, 42, 69). With regard to claims 69-72, Didonato-Tinsley et al. teach that the composition is applied to plant parts including a seed, a leaf, a fruit, a stem, a root, a tuber, and a coleoptile, and to plant parts of lettuce (Para. 45, 58, 67). It is noted that the composition as rendered obvious by Didonato-Tinsley et al. includes all components as claimed. As the composition of Didonato-Tinsley et al. cannot be separated from its functions, the composition would necessarily be capable of coating plant parts to provide a coated plant part including: corn, a Brassica sp., alfalfa, rice, rye, sorghum, millet, sunflower, safflower, soybean, tobacco, potato, peanuts, cotton, sweet potato, cassava, coffee, coconut, pineapple, citrus trees, cocoa, tea, banana, avocado, fig, guava, mango, olive, papaya, cashew, macadamia, almond, sugar beets, sugarcane, oats, barley, tomatoes, green beans, lima beans, peas, cucurbits, ornamentals, and conifers; rice, wheat, corn, barley, millet, sorghum, oat, and rye; a turfgrass plant including annual bluegrass, annual ryegrass, Canada bluegrass, fescue, bentgrass, wheatgrass, Kentucky bluegrass, orchard grass, ryegrass, redtop, Bermuda grass, St. Augustine grass, and zoysia grass; and a cucurbit plant including cucumber, cantaloupe, and musk melon. Response to Arguments In view of Applicant’s amendments, all previous rejections have been withdrawn. Therefore, Applicant’s arguments are moot. However, new rejections have been set forth above. Conclusion No claims are allowable. Previously Presented Art or Record: Bogosian, IDS, US 2013/0324407; Published 2013 (composition for treating a plant or plant part with a composition comprising a Methylobacterium strain and an additional beneficial microorganism). Any inquiry concerning this communication or earlier communications from the examiner should be directed to JENNIFER M.H. TICHY whose telephone number is (571)272-3274. The examiner can normally be reached Monday-Thursday, 9:00am-7:00pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila G. Landau can be reached at (571)272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JENNIFER M.H. TICHY/Primary Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Show 1 earlier event
Feb 13, 2025
Non-Final Rejection mailed — §103
May 13, 2025
Response after Non-Final Action
May 13, 2025
Response Filed
Oct 29, 2025
Response Filed
Feb 19, 2026
Final Rejection mailed — §103
Jul 20, 2026
Request for Continued Examination
Jul 21, 2026
Response after Non-Final Action
Oct 05, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12714729
Method of preparing a faecal microbiota sample
5y 6m to grant Granted Aug 25, 2026
Patent 12702979
Isolation of Different Extracellular Vesicle (EV) Subpopulations
4y 9m to grant Granted Aug 11, 2026
Patent 12697414
ADIPOSE COMPOSITIONS AND METHODS OF USE THEREOF
2y 4m to grant Granted Aug 04, 2026
Patent 12690582
VIABLE CELL COMPOSITIONS, AND METHODS RELATED TO SAME
6y 6m to grant Granted Jul 28, 2026
Patent 12680921
Method and Device for Producing a Film-Shaped Test Body
2y 6m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+34.4%)
2y 11m (~3m remaining)
Median Time to Grant
High
PTA Risk
Based on 618 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month